Search

Search Constraints

You searched for: Date 2017 Author/Creator Mathieu, S.

Search Results

2. Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results. (June 2017)